A Phase III, Open Label, RandomisedControlled, Multi-centre Study to Assess the Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Latest Information Update: 14 Feb 2024
At a glance
- Drugs Famitinib (Primary) ; Sunitinib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 07 Feb 2024 Status changed from recruiting to discontinued.
- 30 Nov 2020 Planned End Date changed from 1 Dec 2030 to 1 Dec 2025.
- 30 Nov 2020 Planned primary completion date changed from 1 Feb 2023 to 1 Dec 2023.